For decades, basal insulin has meant daily injections. Every day, same time, another shot. For the roughly 8.4 million Americans who use basal insulin, that adds up to 365 injections per year, each one requiring discipline, supplies, and a willingness to maintain a routine that never takes a day off.
In March 2026, the FDA approved Awiqli (insulin icodec) — the first once-weekly basal insulin. One injection per week. Fifty-two injections per year instead of 365. The question is not whether this is more convenient (it obviously is), but whether the clinical trade-offs make it a smart choice for your diabetes management.
Quick Answer
Awiqli is non-inferior to Lantus in A1c reduction and offers the massive convenience advantage of once-weekly dosing. It is best suited for type 2 diabetes patients who struggle with daily injection adherence. It is not recommended for type 1 diabetes, pregnancy, or patients who need frequent dose adjustments. If you are well-controlled on daily insulin and do not find it burdensome, the clinical case for switching is incremental. If adherence is a challenge, Awiqli could be transformative.
How Awiqli Works
Insulin icodec (the molecule in Awiqli) is a novel basal insulin analog engineered for ultra-long duration of action. Its half-life is approximately 196 hours (~8 days), compared to 12–14 hours for Lantus and 25 hours for Tresiba.
The extended duration is achieved through three mechanisms:
- Strong albumin binding: Icodec binds tightly to circulating albumin, creating a reservoir that slowly releases active insulin
- Reduced receptor affinity: The molecule is designed to have slower insulin receptor binding, extending the pharmacodynamic effect
- Delayed clearance: The molecular modifications slow hepatic and renal clearance
The result is a flat, sustained insulin effect over 7+ days from a single injection. No peaks, no valleys — just steady basal coverage.
Awiqli vs Daily Basal Insulins
| Feature | Awiqli (Icodec) | Lantus (Glargine U100) | Tresiba (Degludec) | Levemir (Detemir) |
|---|---|---|---|---|
| Dosing | Once weekly | Once daily | Once daily | Once or twice daily |
| Injections/Year | 52 | 365 | 365 | 365–730 |
| Half-Life | ~196 hours | ~12–14 hours | ~25 hours | ~6–8 hours |
| A1c Reduction | 0.7–1.0% | 0.6–0.9% | 0.7–1.1% | 0.5–0.8% |
| Hypo Risk (Severe) | Very low | Low | Very low | Low |
| Hypo Risk (Mild) | Low-moderate | Low | Very low | Moderate |
| Monthly Cost (WAC) | $300–$500 | $100–$300 (biosimilar $50–$80) | ~$400 | $200–$400 |
| Dose Flexibility | Weekly adjustment only | Daily adjustment possible | Daily adjustment possible | Daily adjustment possible |
| Best For | Adherence challenges, simplified regimen | Stable T2D, cost-sensitive | Low hypo risk priority | Twice-daily dosing flexibility |
Efficacy: ONWARDS Trial Results
The ONWARDS clinical trial program (6 trials, 4,000+ patients) compared Awiqli to daily basal insulins across various type 2 diabetes populations.
Key findings (ONWARDS 1, the largest trial):
- Awiqli reduced A1c by 0.93% vs 0.71% for Lantus (statistically non-inferior, with numerical superiority)
- Time in range (70–180 mg/dL) was approximately 71.9% for Awiqli vs 66.9% for Lantus — a clinically meaningful improvement
- Fasting plasma glucose reductions were comparable
- Results were consistent across age groups, BMI levels, and baseline A1c
Translation: Awiqli is at least as effective as Lantus at controlling blood sugar, with some data suggesting it may be slightly better at keeping glucose in the target range throughout the week.
Hypoglycemia Risk
The main safety concern with any insulin is hypoglycemia (low blood sugar).
- Severe hypoglycemia: Very rare with both Awiqli and Lantus (0.1 events per 100 patient-years for both)
- Clinically significant hypoglycemia (<54 mg/dL): Slightly higher with Awiqli (0.30 events per patient-year) vs Lantus (0.16). This difference is small but real.
- Compared to Tresiba: Tresiba has the lowest hypoglycemia risk among daily insulins. Awiqli's risk is slightly higher than Tresiba but similar to Lantus.
The key consideration is that Awiqli's long half-life means hypoglycemia may be harder to resolve quickly — the insulin effect persists for days. For patients prone to hypoglycemia, Tresiba may still be preferable.
Cost Analysis
Awiqli's estimated wholesale acquisition cost (WAC) is $300–$500/month. For context:
- Biosimilar Lantus (glargine): $50–$80/month — the most affordable option by far
- Brand Lantus: $100–$300/month
- Tresiba: ~$400/month
Awiqli is priced similarly to Tresiba but significantly above biosimilar glargine. For patients where cost is the primary concern, generic daily insulin remains the better value. For patients where adherence is the concern, the cost premium may be justified by improved real-world outcomes.
Novo Nordisk offers patient assistance programs with copay support for commercially insured patients and free medication for qualifying low-income patients.
The Convenience Factor
Numbers tell the story:
- 52 injections/year (Awiqli) vs 365 injections/year (daily insulin)
- 86% fewer injections
- One dose day per week instead of a daily commitment
- Easier to maintain routine during travel, illness, or busy periods
For patients in long-term care facilities, Awiqli also reduces nursing workload — weekly insulin dosing is dramatically simpler for staff managing multiple patients.
Who Should Consider Awiqli
- Patients with poor daily insulin adherence (missed doses, inconsistent timing)
- Frequent travelers who find daily injection logistics burdensome
- Patients in long-term care facilities where simplified dosing reduces medication errors
- Patients with needle fatigue who want to minimize injection frequency
- Type 2 diabetes patients who would benefit from the psychological relief of a weekly routine
Who Should Stay on Daily Insulin
- Patients well-controlled on their current regimen with good adherence
- Type 1 diabetes patients — Awiqli is not approved for type 1
- Pregnant patients or those planning pregnancy — insulin needs change rapidly and require daily dose flexibility
- Cost-sensitive patients — biosimilar glargine is 5–10x less expensive
- Patients who need frequent dose adjustments (during illness, surgery, steroid use, etc.) — weekly dosing limits adjustment flexibility
- Patients prone to hypoglycemia who may be better served by Tresiba's ultra-low hypo risk
Bottom Line
Awiqli is a genuine innovation in diabetes care — the first insulin that makes weekly dosing a reality. For patients who struggle with daily adherence, it could meaningfully improve outcomes. For patients who are doing fine on daily insulin, the clinical advantage is modest and must be weighed against higher cost.
Ask your endocrinologist or diabetes care team whether Awiqli is appropriate for your situation. Bring your current A1c, insulin dose, adherence history, and insurance information to the conversation. The future of insulin therapy is more flexible — and weekly dosing is now an option.